ABSTRACT
Background: Several medical therapies have been proposed for the treatment of premature ejaculation [PE]. Paroxetine and tramadol were both reported to be effective in treatment of PE. In this study, the therapeutic effects of tramadol, paroxetine and placebo were compared in treatment of primary PE
Methods: In this randomized, double-blind, placebo-controlled clinical trial, 150 patients were divided into 3 groups. One group was treated with tramadol 50 mg on- demand, the other group took paroxetine 20 mg on-demand and the third group was treated with placebo. Before starting treatment and after 12 weeks, patients were asked to measure their average intravaginal ejaculation latency time [IELT] and fill the PEP [Premature Ejaculation Profile] questionnaire
Results: At the end of the 12th week, the mean IELT and average of PEP scores improved in all 3 groups. The increase in tramadol group was significantly higher than the paroxetine and placebo groups [p<0.0001]. There were no significant differences in terms of side effects between the 3 groups
Conclusion: The results showed that despite an increase in mean IELT and PEP scores in all 3 groups, the rate of improvement in tramadol group was significantly more than the others. Thus, tramadol may be considered as an appropriate alternative therapeutic option for lifelong PE
ABSTRACT
To evaluate the relationship between serum lipids including cholesterol, low-density lipoprotein [LDL], high-density lipoprotein [HDL], and triglyceride and erectile dysfunction [ED]. From January 2000 to June 2003, 100 patients with organic ED, who were referred to our center, were selected and their lipid profile [Cholesterol, Triglyceride, HDL, LDL] were assessed. The results were compared with those in 100 healthy individuals. Mean age of men in the study and control groups were 43.72 +/- 9.76 and 43.59 +/- 10.51 years, respectively. Mean plasma cholesterol and LDL levels in individuals suffering from erectile dysfunction were significantly higher than controls [P = 0.04 and P = 0.02, respectively]. However, no difference in the mean plasma triglyceride and HDL levels was seen. Odds Ratios for high plasma cholesterol level [>240 mg/dl] and high plasma LDL level [>160 mg/dl] were 1.74 and 1.97, respectively [r2 = 0.04 and r2 = 0.04]. Using linear regression analysis, the regression coefficient for cholesterol and LDL versus the International Index of Erectile Dysfunction Questionnaire [IIEF] score were -0.036 and -0.035, respectively [95% confidence interval: 0.98 - 2.5 for cholesterol and 1.13 - 2.81 for LDL]. The impact of total cholesterol and particularly LDL on men's erectile function underlines the role of hyperlipidemia treatment in prevention of ED and emerges a holistic management in ED patients
Subject(s)
Humans , Male , Lipids/blood , /blood , Triglycerides/bloodABSTRACT
This study aimed to compare urinary Tamm-Horsfall protein [THP], citrate, and other inhibitors and promoters of stone formation in calcium stone formers with those in healthy individuals. From January 2002 to June 2004, 100 calcium stone formers [mean age, 38.6 +/- 10.3 years] who had at least 2 episodes of calcium stone formation were compared with 100 healthy individuals [mean age, 33.8 +/- 9.7 years]. Their 24-hour urine THP [using the sodium dodecyl sulfate polyacrylamide gel electrophoresis method], citrate, calcium, uric acid, oxalate, and magnesium values were measured and compared. The mean 24-hour urine THP was 3.3 +/- 8.1 mg in patients in the study group and 4.6 +/- 19.2 mg in controls [P=0.5]. However, THP in individuals with and without bacteriuria was significantly different [15.8 +/- 33.6 versus 2.6 +/- 10.2, P<0.001]. Mean 24-hour urinary calcium, citrate, and oxalate values were 232.6 +/- 95.3 mg and 177.8 +/- 82.7 mg [P<0.001], 132 +/- 103.2 mg and 395 +/- 258.5 mg [P<0.001], and 18.9 +/- 22.5 mg and 10.4 +/- 8.5 mg [P<0.001] in patients in the study and control groups, respectively. There was a significant positive correlation between urinary citrate and promoters of stone formation, including urinary calcium, oxalate, and uric acid, in patients in the control group, but not in patients in the study group. THP in the urine of stone formers is not quantitatively different from that of healthy individuals, but it is different in patients with bacteriuria. Increased urinary excretion of calcium, oxalate, and uric acid in stone formers with no increase in urine citrate may play a role in the pathogenesis of recurrent stone formation